Table 2. The hepatocellular carcinoma highly saturated pathways by targets of validated microRNAs.
| Pathway | Enrichment Ratio | FDR |
|---|---|---|
| KEGG pathway | ||
| 04060: Cytokine-cytokine receptor interaction | 0.17 | 1.80E–18 |
| 05215: Prostate cancer | 0.20 | 3.46E–12 |
| 05220: Chronic myeloid leukemia | 0.22 | 1.92E–11 |
| 05211: Renal cell carcinoma | 0.21 | 1.12E–10 |
| 04012: ErbB signaling pathway | 0.18 | 2.03E–10 |
| 05214: Glioma | 0.22 | 2.37E–10 |
| 05212: Pancreatic cancer | 0.20 | 8.14E–10 |
| 05218: Melanoma | 0.20 | 8.14E–10 |
| 04115: p53 signaling pathway | 0.19 | 4.42E–9 |
| 05223: Non-small cell lung cancer | 0.19 | 5.32E–7 |
| 04930: Type II diabetes mellitus | 0.24 | 6.31E–7 |
| 05219: Bladder cancer | 0.21 | 7.35E–7 |
| 05210: Colorectal cancer | 0.16 | 1.96E–6 |
| 04150: mTOR signaling pathway | 0.17 | 4.05E–6 |
| 05221: Acute myeloid leukemia | 0.16 | 6.67E–6 |
| 05213: Endometrial cancer | 0.15 | 2.74E–5 |
| Panther pathway | ||
| P00002: Alpha adrenergic receptor signaling pathway | 0.31 | 9.74E–22 |
| P00032: Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | 0.32 | 2.29E–21 |
| P00023: General transcription regulation | 0.22 | 1.22E–14 |
| P00006: Apoptosis signaling pathway | 0.20 | 1.32E–11 |
| P00034: Integrin signalling pathway | 0.29 | 3.02E–10 |
| P00005: Angiogenesis | 0.17 | 1.10E–8 |
| P00038: JAK/STAT signaling pathway | 0.45 | 2.30E–8 |
| P00033: Insulin/IGF pathway-protein kinase B signaling cascade | 0.22 | 1.30E–7 |
| P00020: FAS signaling pathway | 0.31 | 4.39E–6 |
| P00025: Hedgehog signaling pathway | 0.26 | 4.71E–6 |
| P00045: Notch signaling pathway | 0.27 | 8.13E–5 |
| P00027: Heterotrimeric G-protein signaling pathway | 0.18 | 8.38E–5 |
FDR, false discovery rate